RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $604 to $712.
RBC Capital Maintains Outperform on Chemed, Raises Price Target to $712
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.